Redoxis focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). 

Redoxis’ core competencies in in Vivo and in Vitro models of autoimmune inflammation are the basis for its CRO services in preclinical drug development and validation. Redoxis’ experienced research team have specialized competencies in immunology, animal models and target validation. The company’s efficient organizational structure affords us a high level of flexibility in the target validation process, meaning Redoxis can quickly validate novel drug targets to develop candidate drugs.